http://www.law360.com/ Latest articles for organization: Endo Pharmaceuticals Copyright 2009 Portfolio Media, Inc. en-US http://www.law360.com/images/headings/logo.gif http://www.law360.com/ http://www.law360.com/articles/125972 Genzyme Corp. has accused Endo Pharmaceuticals Inc. of infringing a patent for Renagel by seeking regulatory permission to sell a generic version of the kidney disease treatment in the U.S. before the patent expires. http://www.law360.com/articles/125972 http://www.law360.com/articles/120449 Endo Pharmaceuticals Inc. has asked a court for permission to intervene in Genzyme Corp.'s Renagel patent infringement case against Impax Laboratories Inc., arguing that Impax challenged a second patent's validity solely in a bid to force first-filer Endo to forfeit its exclusivity period. http://www.law360.com/articles/120449 http://www.law360.com/articles/110041 The U.S. Food and Drug Administration has ordered manufacturers of drugs containing the pain-killing ingredient propoxyphene to boost the products' warning labels to highlight the risk of fatal overdoses. http://www.law360.com/articles/110041 http://www.law360.com/articles/109173 Popular prescription painkillers including Abbott Laboratories' Vicodin and Endo Pharmaceuticals Holdings Inc.'s Percocet may soon be pulled from the market, after a narrow majority of U.S. Food and Drug Administration advisory panel members reportedly voted Tuesday to eliminate the drugs because they contain acetaminophen, which has been linked to liver damage and death. http://www.law360.com/articles/109173 http://www.law360.com/articles/104204 A top Federal Trade Commission official on Wednesday urged lawmakers to pass legislation banning so-called reverse payment patent settlements between brand-name pharmaceutical companies and their generic competitors. http://www.law360.com/articles/104204 http://www.law360.com/articles/94832 A U.K. appeals court has determined that generic-drug makers Sandoz Ltd. and ratiopharm GmbH have infringed the patents of Purdue Pharma LP affiliate Napp Pharmaceutical Holdings Ltd. for the painkiller Oxycontin. http://www.law360.com/articles/94832 http://www.law360.com/articles/91221 An appeals court on Wednesday affirmed a U.S. Board of Patent Appeals ruling that a potentially less toxic method for preparing the pain reliever oxycodone was obvious, barring both parties in the dispute – who each claim to have discovered the process – from moving forward with their respective patent applications. http://www.law360.com/articles/91221 http://www.law360.com/articles/88111 Endo Pharmaceuticals Inc. and Penwest Pharmaceuticals Co. have reached a settlement with Actavis South Atlantic LLC in a patent infringement suit over Actavis' attempt to make and market a generic version of pain medication Opana ER. http://www.law360.com/articles/88111 http://www.law360.com/articles/85707 Indevus Pharmaceuticals Inc. is facing another proposed shareholder class action seeking to block a merger with Endo Pharmaceuticals Holdings Inc., claiming Endo's $4.50 a share offer undervalues the specialty drug company. http://www.law360.com/articles/85707 http://www.law360.com/articles/83434 Difficulties in obtaining injunctive relief in federal court coupled with the increasing number of foreign companies involved in patent litigation are boosting cases at the U.S. International Trade Commission, making legal experience in that forum more important than ever, according to Martin J. Black, chairman of Dechert LLP’s intellectual property group. http://www.law360.com/articles/83434 http://www.law360.com/articles/83088 Indevus Pharmaceuticals Inc. has been hit with two putative class actions by shareholders alleging the specialty drug company and its executives breached their fiduciary duties in connection with a merger proposal by Endo Pharmaceuticals Holdings Inc. http://www.law360.com/articles/83088 http://www.law360.com/articles/73706 Endo Pharmaceuticals Inc. and Penwest Pharmaceuticals Co. accused Barr Laboratories Inc. of patent infringement Monday in their latest action to keep a generic version of the painkiller Opana ER off the market. http://www.law360.com/articles/73706 http://www.law360.com/articles/67904 Purdue Pharma LP and generics maker Mallinckrodt Inc. have struck a deal that will allow Mallinckrodt to market and sell its cheaper version of the brand-name painkiller OxyContin for a licensing fee. http://www.law360.com/articles/67904 http://www.law360.com/articles/67132 Endo Pharmaceuticals Inc. and Penwest Pharmaceuticals Co. have accused Sandoz Inc. of patent infringement in their latest suit to keep a generic version of painkiller Opana ER off the market. http://www.law360.com/articles/67132 http://www.law360.com/articles/64125 Endo Pharmaceuticals Holdings Inc. and Penwest Pharmaceuticals Co. have slapped Impax Laboratories Inc. with a third patent infringement suit over the company's attempts to manufacture its generic version of pain treatment Opana ER. http://www.law360.com/articles/64125 http://www.law360.com/articles/63930 Patent-holding company LecTec Corp. let fly a lawsuit Friday accusing Johnson & Johnson Consumer Cos. Inc. and Endo Pharmaceuticals Inc., among others, of infringing two patents related to adhesive patches. http://www.law360.com/articles/63930 http://www.law360.com/articles/53313 A California federal court has dismissed an Impax Laboratories Inc. case against Medicis Pharmaceutical Corp. for failing to show an immediate controversy regarding a patent for popular acne medication Solodyn. http://www.law360.com/articles/53313 http://www.law360.com/articles/51826 AOL, Twentieth Century Fox Film and Sony Ericsson Mobile were just some of the companies that hired law firms to work on major IP litigation in recent weeks, according to our daily review of court dockets. http://www.law360.com/articles/51826 http://www.law360.com/articles/45345 Endo Pharmaceuticals Holdings Inc. and Penwest Pharmaceuticals Co. have tied Impax Laboratories Inc. into another patent infringement lawsuit as the company moves closer to marketing a generic version of pain treatment Opana ER. http://www.law360.com/articles/45345 http://www.law360.com/articles/44255 Impax Laboratories Inc. is challenging Medicis Pharmaceutical Corp.'s patent for a popular acne medication in hopes of launching a generic version of the drug. http://www.law360.com/articles/44255